Carregant...
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few years including the second-generation proteasome inhibitor carfilzomib which has been appr...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089326/ https://ncbi.nlm.nih.gov/pubmed/27904737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716667275 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|